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Background: The exact origin of cell-free DNA found in spent culture media or 
blastocoel fluid is currently unknown but with the potential to become an improved 
source of DNA for chromosomal analysis than trophectoderm biopsy samples, it 
provides a superior representation of the fetal genetic status. However, the genetic 
material contained within the blastocoel cavity may be more reliable to assessment 
of embryo euploidy in a clinical context than trophectoderm of cell-free DNA.  
Case Presentation: This is the first UK case report where all three sources of DNA 
were analyzed in a clinical setting on 29 th January 2018 at the Centre for Reproduc-
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reimplantation genetic testing for aneuploid-
ies (PGT-A) is a method that aims to de-
scribe the chromosomal complement of em- 
 
bryos. The use of PGT-A to identify euploid em-
bryos, which can then be prioritized for transfer to 
the uterus, has been the subject of significant de-
bate and controversy. Recent literature suggests 
that IVF success (Focusing on ongoing pregnancy 
rates per transfer) can be increased by up to a 30% 
when PGT-A is employed to assist embryo selec-
tion in single embryo transfer cycles (1). Other 
randomized controlled trials have shown signifi-
cantly higher implantation and delivery rate and 
lower multiple pregnancy rates (2, 3). Meta-anal-
yses and systematic reviews have reported in-
creased ongoing pregnancy and live birth rate and 
decreased miscarriage rate in cycles utilizing 




to voice concerns over the clinical value of PGT-
A, questioning its benefit in terms of live birth 
rates and expressing worries that errors in assign-
ing embryo chromosomal status may cause some 
potentially viable embryos to be discarded (6, 7). 
Currently, embryo biopsy is an invasive but indis-
pensable component of the PGT-A procedure. It 
has been argued that it would be advantageous if 
biopsy could be eliminated, since it entails a sig-
nificant additional cost and risks placing the em-
bryo under stress (8). Several attempts to deter-
mine whether or not an embryo is aneuploid by 
inference from its morphokinetic behavior have 
been attempted but have failed to generate suffi-
ciently robust data to support the use of morpho-
logical and/or time-lapse systems for the determi-
nation of embryo ploidy status (9, 10). Other po-
tential approaches for the cytogenetic evaluation 
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of embryos, avoiding the use of embryo biopsy, 
have been reported in the literature. Minimally 
invasive or non-invasive strategies include the 
analysis of blastocoel fluid and spent culture me-
dia, both of which have demonstrated the pres-
ence of genetic material (11-14). However, low 
amplification yield and poor DNA integrity, par-
ticularly affecting blastocoel fluid, posea chal-
lenge for chromosomal analysis. Literature on blas-
tocoel fluid describes a ploidy concordance be-
tween trophectoderm biopsy and the blastocoel 
fluid DNA ranging from 60 to 97% (15, 16). In 
the case of spent embryo culture media, concord-
ance rates between trophectoderm biopsy and me-
dia samples reported by different groups have var-
ied from 70 to 90% (17, 18). However, DNA con-
tamination may be a potential problem. While 
most groups have not recorded an appreciable in-
cidence of contamination, Vera-Rodriguez et al. 
(2018) reported high levels of maternal DNA con-
taminants following amplification and analysis of 
a polymorphic short tandem repeat (STR), with 
only ~8% of the DNA fraction in the embryonic 
culture media being embryonic in origin. Herein, 
a case with the confirmation of ploidy status was 
reported with the aforementioned procedures and 
trophectoderm biopsy. This case provides direct 
evidence that multiple invasive and non-invasive 
techniques can be combined and deployed in the 
clinic in tandem, potentially enhancing diagnostic 
accuracy rates. To the best of our knowledge, this 
case represents the first clinical pregnancy follow-
ing assessment of an embryo using all three of the 
aforementioned procedures.  
 
Case Presentation 
A 43-year-old woman presented for evaluation 
of infertility on 29 th January 2018 at the Centre 
for Reproductive and Genetic Health, London. 
She had secondary infertility for one year and had 
previously had a first trimester miscarriage, which 
was managed conservatively. Her medical history 
was unremarkable. Her ovarian reserve test show-
ed a total antral follicle count of 6, anti-Mullerian 
hormone 4.7 pmol/l, follicle stimulating hormone 
10.10 IU/l and oestradiol <250 pmol/l. Her male 
partner was 33 years old. His medical history was 
unremarkable and his semen analysis was normal. 
The couple was counseled. The patient underwent 
two consecutive cycles of controled ovarian stim-
ulation to optimize the yield of embryos sent for 
PGT-A testing. An antagonist protocol was pre-
scribed with Fostimon® 225 IU and Merional® 
225 IU (IBSA, Italy). Vaginal egg retrieval was 
carried out 37 hr post 10,000 IU of Pregnyl 
(MSD, UK).  
On the first cycle, a total of eight oocytes were 
collected, seven were mature and three exhibited 
normal fertilization at 16-18 hr post intracyto-
plasmic sperm injection (ICSI). A total of three 
top-quality embryos were frozen using the vitrifi-
cation techniques on day 3 of embryo develop-
ment. Embryo vitrification was performed using 
Kitazato vitrification kit with the use of high con-
centrations of cryoprotectants and ultra-rapid cool-
ing to avoid detrimental ice crystal formation 
(20). On a subsequent cycle, a total of four eggs 
were collected all of which were mature and three 
fertilized following ICSI. On day 3 of embryo de-
velopment, the frozen embryos from the previous 
cycle were thawed and all cultured to the blasto-
cyst stage simultaneously. From the frozen thaw-
ed cohort of embryos, one embryo reached the 
blastocyst stage on day 6, while from then fresh 
cohort one embryo formed a blastocyst on day 5 
of development. The blastocyst is an advanced 
stage of embryo development where the embryo 
differentiates into two cell lines, the inner cell 
mass and the trophectoderm, and forms a fluid 
filled cavity (Blastocoel). It is a prerequisite to 
culture embryos to the blastocyst stage prior to 
trophectoderm biopsy.  
The unit policy is to only perform blastocentesis 
on half the embryos reaching the blastocyst stage 
for quality control. Therefore, the day 5 develop-
ing blastocyst was subjected to blastocentesis us-
ing a microinjection pipette prior to trophecto-
derm biopsy (Figure 1). A minimal invasive mi-
cro-puncture was performed between two junc-
tions of cells, the fluid was aspirated and then ex-
pelled into a 0.2 ml Eppendorf tube. The tube was 
immediately placed on an ice rack and stored in a 
-80 oC freezer until analysis. Trophectoderm biop-
sy was then performed immediately using a non-
contact 1.48 µm diode laser (RI, Cornwall, UK) 
with a total of 5-8 trophectoderm cells removed. 
Prior to blastocoelic fluid aspiration and tro-
phectoderm biopsy, the blastocyst was removed 
from the embryoscope slide dish and approxi-
mately 15-20 µl of spent culture media was col-
lected using a sterile individually wrapped 20 µl 
Gilson pipette. The collected media were expelled 
into a 0.2 ml Eppendorf tube and immediately 
placed on a cold rack and stored at -80°C until 
further analysis. The blastocyst was vitrified post 
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biopsy using Cook blastocyst vitrification media 
(Cook, Sydney). 
All three samples containing DNA and a nega-
tive control were sent to our genetic provider, Re-
progenetics UK, where genetic analysis was per-
formed using next generation sequencing (NGS). 
The blastocoel fluid sample and 10 µl of the spent 
media sample were each subjected to a modified 
version of MDA (Qiagen, UK) using a protocol 
developed at Reprogenetics specifically for the 
purpose of amplifying DNA from blastocoel fluid 
and spent media samples (Babariya and Wells, 
unpublished). The amplified products were run on 
a 1% (w/v) agarose gel to check for amplification 
success. Thereafter, Nextera DNA kit (Illumina, 
UK) was used to prepare libraries from success-
fully amplified samples followed by 75 bp paired 
end sequencing on a MiSeq (Illumina). Unfortu-
nately, the blastocoel fluid sample resulted in 
suboptimal amplification and was not subjected to 
NGS. The sequencing data was analyzed using an 
in-house custom algorithm to determine the chro-
mosomal copy number. 
The trophectoderm biopsy results were euploid 
for both the embryos. Analysis of cell-free DNA 
in the corresponding embryo culture media yield-
ed concordant results, indicating that both of the 
embryos were euploid. The patient had a 3D sa-
line infusion sonohysterography on day 12 of the 
cycle, which revealed a normal uterine cavity. She 
was advised to take Primolut® (Bayer Schering 
Pharma, Germany) 5 mg twice daily from day 14 
of the cycle until day 25 with Buserelin® (Sanofi-
Aventis, Germany) from day 21 as per manufac-
turer’s instructions. Buserelin was stopped once 
luteal phase support was commenced. She had a 
baseline scan on day-1–3 to assess the endometri-
um and ovaries. Progynova® (Bayer, UK) 2 mg 
three times daily orally and 2 mg twice daily vag-
inally was prescribed on day-3 of the withdrawal 
bleed. She was advised to have a repeat transvagi-
nal scan 12 days later to assess endometrial thick-
ness. Once the endometrium was >7 mm in thick-
ness and had a triple line on ultrasound, luteal 
support was commenced and embryo transfer was 
booked 6 days later. Luteal support for cryo-
preserved embryo transfer cycles included Utro-
gestan® (Besins, Belgium) 200 mg three times 
daily orally, intramuscular Lentogest (Institut Bi-
ochemique SA, Switzerland) three times per week 
and Crinone® 8% (Merck Serono, UK) twice a 
day per vaginam. These were continued until 10 
weeks of pregnancy.  
The suitable blastocyst was warmed on the day 
of embryo transfer using Cook Warming Kit 
(Cook, Sidney). The patient was instructed to per-
form a urinary pregnancy test 16 days later. As 
the urinary HCG test was positive, the patient was 
advised to come to the unit for serum HCG. Her 
serum hCG was 1312.0 IU/l. Subsequently, scans 
at 6 weeks and 8 weeks of gestation confirmed a 
viable intrauterine singleton pregnancy with nor-
mal foetal development. At the time of the write 
up of the case report, the patient was 20 weeks 
without any reported foetal or obstetric concerns.  
 
Ethical Consideration: This study was approved 
by the IRAS 214276. This report is based on a 
finding of the ongoing prospective study. 
 
Discussion 
This is the first UK case report where non-
invasive PGT-A screening has been applied in a 
clinical setting. The cycle resulted in a viable on-
going pregnancy without a reported risk of aneu-
ploidy using serum screening and ultrasound. Our 
case report suggests that it is straightforward, from 
a logistical and technical perspective, to incorpo-
rate the sampling of blastocoel fluid and spent cul-
ture medium into routine clinical practice. While 
our report cannot provide firm conclusions con-
cerning the efficiency or accuracy of testing based 
upon sources of cell-free DNA, it was the case that 
results from spent culture media were concordant 
with those obtained from trophectoderm biopsy for 
both embryos tested. This suggests that embryo 
culture medium may indeed provide source of cell-
free DNA suitable for non-invasive PGT-A (niPGT- 
Figure 1. All DNA source for PGT-A were individually ex-
pelled into eppendorf tubes and stored at -80°C until analysis 
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A). In this case study, blastocoel fluid failed to 
yield DNA suitable for subsequent analysis. This 
mirrors our wider experience with this source of 
cell-free DNA and suggests that the blastocoel 
may be a less reliable source of embryonic DNA 
for niPGT-A than spent media. However, the tech-
nique of blastocentesis appears to be relatively 
safe and no evidence of an adverse impact was 
seen upon embryo development following the pro-
cedure in this case. 
Invasive trophectoderm biopsy whether for an-
euploidy screening or for testing of monogenic 
disorders or chromosomal rearrangements remains 
the gold standard method to obtain embryonic 
DNA (8). Even though an international consensus 
does not yet exist regarding the clinical practice of 
PGT-A, laboratory protocols have continued to 
evolve and are now highly optimized in order to 
yield a genetic result. In this case report, our pa-
tient had two chromosomally normal embryos suit-
able for transfer, despite the fact that the euploidy 
rate for individual blastocysts produced by a pa-
tient in this age group is typically <20%.  
Our case report provides support for the notion 
that cell-free DNA in spent culture media could be 
potentially used for non-invasive PGT-A, either to 
supplement results obtained using embryo biopsy 
or to entirely replace the biopsy procedure. Clearly, 
large multicenter studies will be required to clarify 
the value of niPGT-A strategies such as the one 
described in this paper. An ongoing preliminary 
study at our clinic shows an amplification rate of 
over 65% for spent culture media and trophecto-
derm with good concordance for euploid embryos 
(Unpublished data). Release of cell free DNA oc-
curs in human embryo when cultured in vitro via 
apoptosis and perhaps also via other mechanisms 
(17). Kuznyetsov et al. (2018) recently analyzed 
cell free DNA from fresh cultured embryos (24-48 
hr), which showed 100% amplification rate and 
98.2% concordance with trophectoderm cells. How-
ever, the mean amount of DNA obtained from the 
embryo culture media in fresh embryos was lower 
compared to vitrified-warmed blastocysts in their 
study.  
In contrast to the cell-free DNA in embryo cul-
ture medium, the results from blastocentesis ob-
tained during the current case were inferior to 
some other published reports (12, 18, 21). This 
poor performance is in accord with our wider ex-
perience when attempting to harvest and analyze 
blastocoel DNA, in which only 25% of samples 
have successfully been amplified. This provides 
some evidence, albeit from a limited study, that 
genetic material contained within the blastocoel 
cavity may be more challenging to utilize in a 
clinical context than other sources of cell-free 
DNA. While some studies have reported DNA 
amplification success rates ranging from 72-96.4% 
for blastocoel fluid and a high degree of diagnos-
tic concordance for ploidy status (12, 18, 21), it 
appears that optimal results require highly ex-
panded blastocysts, which were not always avail-
able in the current study. Additionally, the lack of 
amplification and concordance that we have ob-
served using this material may be related to the 
need to store the sample and then ship to a refer-
ence laboratory, potentially allowing further deg-
radation of the DNA. It is also worth noting that, in 
comparison to the collection of spent culture medi-
um, blastocentesis is a relatively invasive proce-
dure, requiring greater skill, more of the embryol-
ogist’s time and a greater exposure of the embryo 
to suboptimal environmental conditions outside 
the incubator.  
 
Conclusion 
Trophectoderm biopsy has been instrumental in 
improving the accuracy rates and diagnostic effi-
ciencies of PGT-A and PGT-M. However, the 
technique is highly skilled, time consuming, and it 
necessitates the purchase and maintenance of a 
laser, and carries with it a small risk of embryonic 
damage (Although minimized in experienced hand-
s). In addition, a limitation to the accuracy of 
PGT-A following trophectoderm biopsy is chro-
mosomal mosaicism, which poses significant risks 
for misdiagnosis, as there may be cases where tro-
phectoderm cells do not reflect the chromosomal 
status of the entire embryo (2).  These are some of 
the combined factors driving the need for alterna-
tive, preferably non-invasive, PGT-A methods. 
The exact origin of cell-free DNA found in spent 
culture media or blastocoel fluid is currently un-
known, but if this is shown to predominantly orig-
inate from the ICM, then blastocoel fluid might 
prove to be an even more appropriate source of 
DNA for chromosomal analysis than trophecto-
derm biopsy samples, providing a superior repre-
sentation of the fetal genetic status. Like any new 
technology in reproductive medicine, it is para-
mount to understand the clinical implications of 
applying the technique in a clinical setting. The 
experience of this study suggests that removal of 
blastocoel fluid, sampling of spent culture media, 
and trophectoderm biopsy can be carried out in 
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parallel. It is possible that gathering genetic in-
formation from two or three independent samples 
of embryo DNA might provide benefits in terms 
of enhanced diagnostic accuracy, potentially clari-
fying the cytogenetic status of mosaic embryos. In 
the future, if appropriately validated and proven to 
be accurate, niPGT-A methods might even replace 
trophectoderm biopsy, reducing costs and risks of 
aneuploidy screening.  
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